Sponsored Events

 

SPE1.    CIRCADIAN RHYTHM DISTURBANCES AND DEPRESSION
(organized by Servier)

(September 18, 14.30-16.00)

SPE1.1    The circadian basis of mood disorders: the evidence
F. Turek (USA)

SPE1.2    Circadian rhythms at the core of depression
A. Lewy (USA)

SPE1.3    Regulation of circadian rhythms as a treatment approach for depressed patients
P. Courtet (France)

---

OT1.    OLD PROBLEMS AND NEW PERSPECTIVES IN NEUROSCIENCE DRUG DEVELOPMENT
(organized by Eli Lilly and Company)

(September 18, 15.00-16.00)

OT1.1    Unexpected results with a gamma secretase inhibitor for Alzheimer's disease: implications for the amyloid hypothesis
D. Henley (USA)

OT1.2    Glutamate and schizophrenia. Role of metabotropic receptor agonists
B. Kinon (USA)

OT1.3    Partial response: the unmet need in patients with major depressive disorder
S. Dubé (USA)

---

MTE1.    LONG-TERM TREATMENT OF SCHIZOPHRENIA: WHERE ARE WE, WHAT CAN WE ACHIEVE?
(Organized by Janssen-Cilag)

(September 19, 12.30-13.30)

MTE1.1    The impact of the early intervention in schizophrenia on patient outcomes
H.-J. Möller (Germany)

MTE1.2    Current evidence for long-acting injectable antipsychotics in the long-term management of schizophrenia
A. Schreiner (Germany)

---

SPE2.    CHALLENGING DEPRESSIVE SYMPTOMS IN MOOD DISORDERS
(organized by AstraZeneca)

(September 19, 12.30-14.30)

SPE2.1    Treatment options in bipolar disorder: a question of balance
M. Tohen (USA)

SPE2.2    Insights into the potential mechanisms of efficacy of atypical antipsychotics
L. Yatham (Canada)

SPE2.3    Complexities in practice
G. Vázquez (Argentina)

---

SPE3.    FACING THE COMPLEX CHALLENGES OF ACHIEVING MEANINGFUL REMISSION WITH ANTIPSYCHOTIC TREATMENTS
(organized by Lundbeck)

(September 19, 12.30-14.30)

SPE3.1    Managing the complex forms of bipolar I disorder and schizophrenia: beyond symptomatic remission
E. Vieta (Spain)

SPE3.2    Receptor pharmacology of asenapine, an atypical antipsychotic: differentiation and clinical relevance
M. Shahid (UK)

SPE3.3    Achieving effective remission with asenapine for patients with bipolar I disorder
R. McIntyre (Canada)

SPE3.4    Improving patient outcomes in schizophrenia: optimising short- and long-term treatment using asenapine
L. Cortese (Canada)

---

SPE4.    AN INNOVATIVE ANTIDEPRESSANT TREATMENT TO SATISFY PATIENTS' NEEDS
(organized by Servier)

(September 20, 12.30-14.30)

SPE4.1    Management of depression with agomelatine
G. Hajak (Germany)

SPE4.2    Agomelatine: an innovative pharmacological profile for a different mode of action
G. Racagni (Italy)

SPE4.3    Evidence-based antidepressant efficacy of agomelatine
P.-M. Llorca (France)

SPE4.4    Outcome of depression is improved by addressing patient heterogeneity
M. Marquez (Argentina)

---

SPE5.    BIPOLAR DISORDER: FOCUS ON CLINICAL MANAGEMENT
(organized by Glaxo)

(September 20, 12.30-14.30)

SPE5.1    Consensus guideline on the management of bipolar depression
M. Frye (USA)

SPE5.2    Co-morbidities of bipolar disorder
S. McElroy (USA)

SPE5.3    Bipolar disorder management in Latin America
G. Vazquez (Argentina)

---

SPE6.    FROM DEPRESSION TO RECOVERY: AN OPTIMIST'S APPROACH
(organized by Lundbeck)

(September 20, 12.30-14.30)

SPE6.1    Severe depression in focus
C. Nelson (USA)

SPE6.2    Making the most of our existing treatments
G. Papakostas (USA)

SPE6.3    Exploring the validity of naturalistic data: the case of escitalopram
H.-J. Möller (Germany)

---

SPE7.    WHEN TREATMENT FAILS: THE ROLE OF ATYPICAL ANTIPSYCHOTICS IN MAJOR DEPRESSIVE DISORDER
(organized by AstraZeneca)

(September 21, 12.30-14.30)

SPE7.1    When treatment fails: augmentation with atypical antipsychotics in major depressive disorder
M. Thase (USA)

SPE7.2    Targeting symptomatic control and functional recovery in patients with major depressive disorder
P. Gorwood (France)

SPE7.3    The challenge of the complex patient
R. McIntyre (Canada)

---

SPE8.    MAJOR DEPRESSION: OUR HERITAGE AND OUR FUTURE
(Organized by Eli Lilly and Company)

(September 21, 12.30-14.30)

SPE8.1    The heritage of major depression: past treatments, stigmas, and impact
N. Sartorius (Switzerland)

SPE8.2    The future is the future: neurobiology and genetics
F. Kapczinski (Brazil)

SPE8.3    The future is now: individualized patient outcomes
S. Kennedy (Canada)

Discussant: J.M. Menchón (Spain)

---

MTE2.    SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS AS FIRST LINE TREATMENT (I)
(organized by Pfizer)

(September 21, 12.30-13.30)

MTE2.1    Serotonin-norepinephrine reuptake inhibitors as first line treatment: relapse and remission
S. Montgomery (UK)

---

MTE3.    SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS AS FIRST LINE TREATMENT (II)
(organized by Pfizer)

(September 21, 13.30-14.30)

MTE3.1    Serotonin-norepinephrine reuptake inhibitors as first line treatment: drug to drug interactions
M. Thase (USA)

---

SSp1.    LA DEPRESIÓN COMPLEJA
              (organized by Baliarda)

              (September 20, 12.30-14.30)

             SSp1.1     Depresión bipolar
                C. Lamela (Argentina)

SSp1.2    Depresión psicótica
M. Marinelli (Argentina)

SSp1.3    Depresión mayor resistente
S. Halsband (Argentina)